1. Product Specifications & Comparative Analysis

2. Clinical Applications & Indications

Approved Uses

• Chronic immune thrombocytopenia (ITP) in patients ≥6 years unresponsive to corticosteroids/immunoglobulins
• Severe aplastic anemia (SAA) refractory to immunosuppressive therapy
• Hepatitis C-associated thrombocytopenia (selected markets)

Off-Label Applications

• Chemotherapy-induced thrombocytopenia
• Myelodysplastic syndromes with thrombocytopenia

3. Administration Protocols

Dosing Guidelines

Critical Administration Notes

• Take on empty stomach (1hr pre-meal/2hr post-meal)
• 4-hour separation from polyvalent cations (Ca²⁺, Fe³⁺, etc.)
• Weekly platelet monitoring during dose adjustment

4. Adverse Effects & Risk Management

Common Reactions (≥5% incidence)

• Hepatic enzyme elevation (ALT/AST)
• Headache (22%), nausea (15%)
• Thrombocytosis risk (platelets >400K/μL)

Black Box Warnings

• Hepatotoxicity: Monitor LFTs baseline and q2wk
• Thrombotic risk: Caution in patients with cardiovascular comorbidities

5. Verified Clinical Case Studies

Case 1: Chronic ITP Management

Patient Profile: 45-year-old female with ITP (platelets 15K/μL) refractory to IVIG
Intervention: Initiated 25mg daily with weekly monitoring
Outcome: Platelets stabilized at 85K/μL by week 8 without bleeding events

Case 2: Hepatic Impairment Adjustment

Patient Profile: 62-year-old male (Child-Pugh B) post-HCV therapy
Intervention: 25mg QOD regimen with extended monitoring
Outcome: Sustained platelet count >50K/μL for antiviral continuation